繁體中文 简体中文

研究發表

109年度研究論文

篇序

作者
(順位)

論文題目 發表雜誌名稱
(
含年月/卷期/頁次)
屬性
(SCI、SSCI、IEEE)
1  杜漢祥(3) Association of adherence to antiretroviral therapy with economic burden of cardiovascular disease in HIV-infected population. Eur J Prev Cardiol. 2020 Mar 2:2047487320908085. SCI 
2 杜漢祥(2)  Early scale-up of antiretroviral therapy at diagnosis for reducing economic burden of cardiometabolic disease in HIV-infected population. AIDS. 2020 May 1;34(6):903-911. SCI 
3

杜漢祥(1)
湯宏仁(7)

Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy. Int J Infect Dis. 2020 Feb;91:44-49. SCI 
4 杜漢祥(4)  Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention - 2018 update. J Microbiol Immunol Infect. 2020 Feb;53(1):1-10. SCI 
5 湯宏仁(9)  Be Careful with Adverse Events Caused by Cefoperazone-Sulbactam Antimicrob Agents Chemother 2020 Jan 27;64(2):e02028-19. SCI 
6 湯宏仁(1)  Carbapenem/β-lactamase inhibitor combination in complicated urinary tract infection. J Infect 2020 Jan;80(1):121-142. SCI 
7 湯宏仁(1)  Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia Lancet Infect Dis 2020 Jan;20(1):20 SCI 
8 湯宏仁(C)  Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis Medicine (Baltimore) 2020 Feb;99(8):e19321. SCI 
9 湯宏仁(C)  Antimicrobial ability and mechanism analysis of Lactobacillus species against carbapenemase-producing Enterobacteriaceae J Microbiol Immunol Infect 2020 Feb 15;S1684-1182. SCI 
10

蘇柏安(4)
湯宏仁(8)

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products. Antibiotics (Basel) 2020 Feb 12;9(2):77 SCI
11 湯宏仁(C)  The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials Int J Antimicrob Agents 2020 Feb;55(2):105858. SCI 
12 湯宏仁(8)  The intracellular seven amino acid motif EEGEVFL is required for matriptase vesicle sorting and translocation to the basolateral plasma membrane PLoS One 2020 Feb 12;15(2):e0228874 SCI 
13 蘇柏安(1)
湯宏仁(3) 
In Vitro Synergy of Pongamia pinnata Extract in Combination with Antibiotics for Inhibiting and Killing Methicillin-Resistant Staphylococcus aureus. Antibiotics (Basel) . 2020 Feb 29;9(3):103 SCI
14 湯宏仁(7)  Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy. Int J Infect Dis . 2020 Feb;91:44-49. SCI
15 湯宏仁(4)  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents . 2020 Mar;55(3):105924. SCI 
16 湯宏仁(1)  The Safety of Eravacycline in the Treatment of Acute Bacterial Infection Clin Infect Dis 2020 Jun 10;70(12):2750-2751. SCI
17 湯宏仁(1)  Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia. Medicine (Baltimore) 2020 Jul 17;99(29):e21223. SCI 
18 湯宏仁(1)  Plazomicin-associated Nephrotoxicity Clin Infect Dis 2020 Aug 14;71(4):1130-1131. SCI 
19 湯宏仁(1)  The clinical efficacy of lefamulin in the treatment of elderly patients with community-acquired bacterial pneumonia J Thorac Dis . 2020 Aug;12(8):4588-4590. SCI 
20 湯宏仁(3)  Collateral benefits on other respiratory infections during fighting COVID-19. Med Clin (Engl Ed). 2020 Sep 25;155(6):249-253. SCI 
21 湯宏仁(1)  Lefamulin for treating community-acquired bacterial pneumonia in adult patients aged < 65 years. Clin Infect Dis. 2020 Sep 12;71(6):1582. SCI 
22 湯宏仁(19)  National Surveillance of Antimicrobial Susceptibility of Bacteremic Gram-Negative Bacteria with Emphasis on Community-Acquired Resistant Isolates: Report from the 2019 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) Antimicrob Agents Chemother. 2020 Sep 21;64(10) SCI 
23 湯宏仁(14)  Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV J Antimicrob Chemother 2020 Oct 1;75(10):2986-2993. SCI 
24  湯宏仁(1) Clinical efficacy and safety of novel carbapenem/β-lactamase inhibitor combinations against carbapenem-non-susceptible Gram-negative bacterial infection.  J Glob Antimicrob Resist 2020 Dec;23:111-112. SCI
25

陳宏睿(1)
湯宏仁(2)

Warning signs and severe dengue in end stage renal disease dialysis patients. J Microbiol Immunol Infect. 2020 Dec;53(6):979-985. SCI
26 湯宏仁(C)  Impact of COVID-19 preventative measures on dengue infections in Taiwan. J Med Virol 2020 Nov 3. doi: 10.1002/jmv.26650. SCI
27 湯宏仁(3)  UvrY is required for the full virulence of Aeromonas dhakensis Virulence 2020 Dec;11(1):502-520. SCI
28 陳宏睿(1)
湯宏仁(4)
蘇柏安(5) 
The implementation of an active surveillance integrating information technology and drive-through coronavirus testing station for suspected COVID-19 cases. J Infect. 2020 Sep 3 : 4831. SCI
29 陳宏睿(1)
湯宏仁(C) 
傳染性氣溶膠 (aerosols) 的顆粒大小對感染控制的意義 感染控制雜;2020;30:319-325  
30 陳宏睿(1)
湯宏仁(2) 
新冠肺炎之實際照護經驗 內科學誌 2020:31:262-265  
21 李健明(3) Symmetric Cryptography With Shift 2 n-1 , Hash Transformation, Optimization-Based Controller for Medical Image Infosecurity: Case Study in Mammographic Image IEEE Photonics Journal, Vol. 12, No. 3, 2020, pp. 1-16 SCI/SCIE
22 李健明(3) Medical Image Infosecurity Using Hash Transformation and Optimization-Based Controller in a Health Information System: Case Study in Breast Elastography and X-Ray Image IEEE Access, Vol. 8, 2020, pp. 61340-61354 SCI/SCIE